Paul Sauer - 30 Dec 2022 Form 4 Insider Report for Vaxcyte, Inc. (PCVX)

Reporting relationship: SVP Process Dev, Manufacturing
Issuer ticker: PCVX
Reported as of: 30 Dec 2022
Net transaction value: $0
SEC form: 4
Accepted by SEC: 04 Jan 2023, 15:32:05 UTC
Prior SEC filing: 07 Sep 2022
Source filing: View source filing
Reporting owner signature: Paul Sauer, by /s/ Ron A. Metzger, Attorney-in-Fact

Key filing fact

Paul Sauer filed Form 4 for Vaxcyte, Inc. (PCVX) on 04 Jan 2023.

Key facts

This page summarizes Paul Sauer's Form 4 filing for Vaxcyte, Inc. (PCVX).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 04 Jan 2023, 15:32.

Change

Previous filing in this sequence was filed on 07 Sep 2022.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

PCVX transaction Derivative

Stock Option (right to buy)

Award

Transaction value: $0
Shares: +15,000
Change %
Price: $0.000000
Shares after: 15,000
Date: 30 Dec 2022
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 15,000
Exercise price: $47.95
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Section 16 status

Paul Sauer is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.

Explanation of responses 1 footnote

Footnote F1

1/48 of shares subject to the option vest on January 30, 2023, and 1/48 of the shares vest monthly thereafter, subject to Reporting Person's continuous service with the Issuer through each such date.